Babylon Health

๐Ÿ“‚ Healthtech๐Ÿ“‚ Artificial Intelligence๐Ÿ“ London๐Ÿ—“๏ธ Founded: 2013

Company born in London in 2013 with digital doctor consultations and AI tools for patients. A unicorn in 2019, listed on the NYSE in 2021, assets sold to eMed in 2023.

Europe's most interesting startup stories. Every week.

No spam. Unsubscribe anytime.

About Babylon Health

Babylon offered virtual consultations and digital care, with the Babylon 360 value-based care model and digital tools for patients and clinicians through Babylon Cloud Services. It worked with insurers such as Bupa. Founded in London in 2013 by Ali Parsa, it raised a $550M Series C in 2019 at a valuation above $2B and was listed on the NYSE on 22/10/2021 through a SPAC. On 31/08/2023 it sold its UK assets to eMed out of administration; the UK holding was dissolved on 20/11/2024. It is no longer an independent startup.

The Story

Babylon began in London in 2013 with Ali Parsa, became a unicorn in 2019 and listed in 2021; in 2023 its UK assets were sold to eMed.

Products & Services

Key Products

  • Consulti medici virtuali
  • Babylon 360 (value-based care)
  • Babylon Cloud Services

Core Use Cases

  • Consulting a doctor remotely
  • Managing care with value-based models
  • Offering digital tools to patients and clinicians

Market & Clients

Geographic Presence

GBUS

Funding & Investors

Total Funding

Totale primario completo e riconciliato non verificato. Subtotale isolabile circa $165M (A circa $25M + B circa $60M + placement 2022 $80M); le tre cifre di equity pre-SPAC A+B+C (circa $635M) non certificano nuova cassa incassata. Esclusi: grant Gates Foundation $750.000 (2017), convertible loan notes 2020 ($30M + $70M), prestito VNV $15M (07/2021), bond $50M nominali (08/2021), notes AlbaCore $200M (04/11/2021) e $100M (31/03/2022), bridge 2023 (fino a $34,5M + $34,5M + $11,5M nominali). PIPE/SPAC del 21/10/2021: $230M ai venditori secondo Alkuri, $224M alla societร  come capital contribution secondo il 10-K, discrepanza non risolta. Storico 2013-2015 non verificato

Latest Valuation

Oltre $2B al Series C (02/08/2019; $2B post-money secondo Kinnevik, nell'ipotesi di closing finale a $500M). Pro forma SPAC circa $4,2B equity e $3,6B EV (03/06/2021), non capitalizzazione di borsa. Valore corrente non verificato (2019)

Funding Rounds

  • 2016 - Series A: circa $25M
    Lead: Kinnevik
  • 2017 - Series B: ยฃ48M ($60M)
    Lead: Kinnevik
  • 2019 - Series C: $550M
  • 2022 - Private placement: $80M

Key Investors

KinnevikVostok New VenturesPIFERGO FundHoxton VenturesNNS Holdings

Founding Team

Founders

Ali ParsaFondatore e CEO (10/11/2022)

Key Executives

  • David Humphreys - CFO (10/11/2022)

Key Metrics

Ricavi 2022$1.109,7M (2022)
Ricavi Q3 2022$288,9M (2022)

Similar Startups

๐Ÿ“ London

Isomorphic Labs

Isomorphic Labs applies advanced AI models โ€” including those underlying AlphaFold โ€” to drug discovery and design, aiming to transform molecular biology into a computational process and radically accelerate therapeutic pipelines.

Read Analysis
๐Ÿ“ London

Frontier Health

London healthtech developing Juno, an AI agent supporting hospital administrative staff.

Read Analysis
๐Ÿ“ London

Semble

UK healthtech company offering a unified platform to manage patient journeys, clinical workflows and administrative operations.

Read Analysis

Sources

๐ŸŽ™๏ธ Scalable Podcast โ€” European startup stories ยท ๐Ÿ‡ฎ๐Ÿ‡น in Italian
Spotify ๐ŸŽง Apple